Results 51 to 60 of about 1,428 (167)

Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus

Journal of Clinical Medicine Research, 2020
Patients with type 2 diabetes mellitus (T2DM) are at increased risk for impairments in diastolic relaxation and heart failure with preserved ejection fraction (EF). Recent clinical data suggest that several sodium glucose transporter-2 (SGLT2) inhibitors are found to reduce cardiovascular disease (CVD) events in elderly diabetic patients, but the ...
Higashikawa, Toshihiro, Ito, Tomohiko, Mizuno, Takurou, Ishigami, Keiichirou, Kohori, Masaru, Mae, Kunihiro, Usuda, Daisuke, Takagi, Susumu, Sangen, Ryusho, Saito, Atsushi, Iguchi, Masaharu, Kasamaki, Yuji, Fukuda, Akihiro, Kanda, Tsugiyasu, Okuro, Masashi   +14 more
openaire   +3 more sources

Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance [PDF]

, 2020
新潟大学博士(医学)Aims To examine the effects of a sodium–glucose co-transporter 2 (SGLT2) inhibitor, tofogliflozin, on resting heart rate by exploring baseline factors that independently influenced changes in the resting heart rate.
Nojima, Toshiaki, 178229
core   +1 more source

Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)

Contemporary Clinical Trials Communications, 2020
Background: The incidence of nonalcoholic fatty liver disease (NAFLD) has increased recently and is related to obesity and the associated surge in type 2 diabetes mellitus (DM) and metabolic syndrome diagnoses.
Anna Ozaki, Masato Yoneda, Takaomi Kessoku, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Eiji Sakai, Masataka Taguri, Takeharu Yamanaka, Tomoyuki Iwasaki, Takeo Kurihashi, Satoru Saito, Atsushi Nakajima   +14 more
doaj   +1 more source

Effect of Tofogliflozin on Skeletal Muscle Mitochondrial Function in Male Diabetic Mice With Muscle Atrophy. [PDF]

J Endocr Soc
Abstract Sodium-glucose cotransporter-2 (SGLT2) inhibitors are effective medications for type 2 diabetes (T2D), chronic kidney disease, and chronic heart failure regardless of diabetic status. However, concerns remain about their potential to reduce skeletal muscle mass.
Kishida C, Murakoshi M, Sakuma H, Shibata T, Suzuki Y, Gohda T.   +5 more
europepmc   +4 more sources

Changes in the estimated glomerular filtration rate and predictors of the renal prognosis in Japanese patients with type 2 diabetes: A retrospective study during the 12 months after the initiation of tofogliflozin.

PLoS ONE, 2023
BackgroundThe changes in the estimated glomerular filtration rate (eGFR) and predictors of the renal prognosis were retrospectively assessed over the 12 months after the initiation of tofogliflozin, which has the shortest half-life among sodium-glucose ...
Hiroyuki Ito, Hideyuki Inoue, Takuma Izutsu, Suzuko Matsumoto, Shinichi Antoku, Tomoko Yamasaki, Toshiko Mori, Michiko Togane   +7 more
doaj   +1 more source

Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes

Journal of Clinical Medicine Research, 2016
Some patients with type 2 diabetes mellitus (T2DM) on insulin have poor glycemic control and require add-on therapy to reach target glucose values. Increased insulin doses or the addition of an oral antidiabetic drug (OAD) may improve glycemic control, but many patients fail to achieve target values.
Suzuki, Katsunori, Mitsuma, Yurie, Sato, Takaaki, Anraku, Takumi, Hatta, Mariko   +4 more
openaire   +3 more sources

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin [PDF]

Diabetes, Obesity and Metabolism, 2018
An integrated analysis was performed with data from 4 phase 2 and phase 3 studies of tofogliflozin in which patients with type 2 diabetes mellitus received the sodium‐glucose cotransporter 2 inhibitor tofogliflozin for up to 24 weeks. Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric acid (UA) levels, and log
Motoshi Ouchi, Kenzo Oba, Kohei Kaku, Hideki Suganami, Akihiro Yoshida, Yasunori Fukunaka, Promsuk Jutabha, Asuka Morita, Naoyuki Otani, Keitaro Hayashi, Tomoe Fujita, Tatsuya Suzuki, Masahiro Yasutake, Naohiko Anzai   +13 more
openaire   +2 more sources

Additional file 2 of Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial

, 2023
Additional file 2.
Tsunehiko Yamamoto (4915153), Satoru Sumitani (4915135), Hiroki Yokoyama (3607238), Ken Kato (785312), Hidenori Yoshii (4915147), Masahiro Hatazaki (10747817), Mamiko Tsugawa (4915159), Nobuichi Kuribayashi (4915156), Yasunori Sato (491973), Isao Hayashi (4915165), Tomoya Mita (3821596), Iichiro Shimomura (126258), Satoshi Kawashima (31304), Keisuke Kosugi (4915150), Hideaki Kaneto (4915144), Kentaro Ohtoshi (4915162), Yosuke Okada (485759), Takeshi Osonoi (1951555), Hirotaka Watada (131439), Kazuhisa Maeda (387079), Toshihiko Shiraiwa (4915138), Akira Kurozumi (6893570), Tetsuyuki Yasuda (4915141), Naoto Katakami (4845757), Tadashi Nakamura (323696), Kayoko Ryomoto (9107373)   +25 more
core   +1 more source

Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Frontiers in Medicine, 2022
ObjectiveTo evaluate the effects of vitamin E, pioglitazone, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with non-alcoholic fatty liver disease (NAFLD).DesignA network meta-analysis.
Qian Luo, Qian Luo, Ruojun Wei, Ruojun Wei, Yuzi Cai, Yuzi Cai, Qihan Zhao, Qihan Zhao, Yuning Liu, Yuning Liu, Wei Jing Liu, Wei Jing Liu   +11 more
doaj   +1 more source

Tofogliflozin decreases body fat mass and improves peripheral insulin resistance [PDF]

Diabetes, Obesity and Metabolism, 2018
The impact of tofogliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM) was investigated using the hyperinsulinaemic‐euglycaemic clamp method in a single‐arm, open‐label study. The following variables were compared between before and after tofogliflozin
Ren Matsuba, Ikuro Matsuba, Mototsugu Shimokawa, Yoshio Nagai, Yasushi Tanaka   +4 more
openaire   +2 more sources